Zevra Therapeutics heads into the post-earnings stretch with a clean beat under its belt and shorts sitting at a meaningful but steady 8.5% of the float.
Q1 2026 results, reported after the close on May 6, came in well ahead of expectations. Adjusted EPS landed at $0.18, more than double the $0.08 consensus estimate. Revenue of $36.2 million beat the $32.0 million forecast — a strong continuation of the MIPLYFFA ramp that drove full-year 2025 sales to $106.5 million, up from just $23.6 million the prior year. The stock entered the session having already gained 7.2% on the week, pulling the one-month gain to nearly 13%. With the print now out, the question for the market is whether that momentum holds.
Short interest has been subdued and is not a central tension here. The float is 8.5% short — real but not extreme — and has barely moved over the past month, down roughly 1.7% on a 30-day basis while edging up just 1.5% on the week. The borrow market reflects the same indifference: cost to borrow is a negligible 0.51%, and availability in the lending pool is generous, running well below the 52-week utilisation peak of 44.9% that characterised a tighter period earlier in the year. Short sellers are not pressing the thesis aggressively. Options positioning has turned slightly more defensive than recent norms, with the put/call ratio at 1.02 against a 20-day average of 0.93, but the z-score of 0.89 puts that well within a normal range. This looks more like routine pre-earnings hedging than a conviction bet on the downside.
The Street is constructive. Seven analysts carry buy-equivalent ratings. The most recent initiation came from BTIG in mid-March, where analyst Kambiz Yazdi started coverage with a Buy and a $23 target — almost double the price at the time of writing. Mean target price of $22.78 implies roughly 115% upside from current levels at $10.61, though that gap also warrants a note of caution: targets set earlier in 2025 ranged as high as $29 before being trimmed in November, and the stock has been compressing back toward those marks. The 2025 earnings pivot — from a $105.5 million net loss to $83.2 million net income — is the anchor for the bullish case, alongside a growing MIPLYFFA patient base and a potential EU filing in the second half of 2025. The bear case centres on execution risk: payer coverage gaps, slower-than-modelled Olpruva uptake, and the near-term drag of non-cash charges. The company's EPS surprise factor score ranks in the 95th percentile of the universe, which is the clearest quantitative signal of how consistently it has been landing ahead of consensus.
Institutional ownership is building. FMR (Fidelity) added 758,873 shares in Q1 2026, making it the largest single net buyer among top holders. Aigh Capital Management entered the register with a fresh 1.2 million share position as of March 31. BlackRock added nearly 470,000 shares in the same period. Combined, the three major additions total more than 2.4 million shares in a single quarter — a meaningful accumulation in a stock with a relatively tight free float. The picture from insiders is less clear: CEO Neil McFarlane received equity awards in late January but sold 91,000 shares on February 2 at around $9.38, followed by a smaller sale on February 9. Sales following award grants are routine, but the net insider activity over 90 days is approximately 181,000 shares bought (net of sells across all insiders), with the awards dominating the numerator.
The March earnings print — when the stock jumped 23% in a single session following full-year 2025 results — is the benchmark reaction the market will now compare against. That move was driven by the full-year revenue surprise and the swing to profitability. Tonight's Q1 beat is a continuation, not a step-change of the same magnitude. A follow-on earnings call is scheduled for May 11, giving management another window to update on patient enrolment trends and any progress on the EU filing timeline — those two items are the ones worth watching most closely.
See the live data behind this article on ORTEX.
Open ZVRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
